Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company announced that it has achieved a crucial milestone-enrolling the first patient in its Phase 3 trial of PF614-its lead drug candidate that aims to redefine pain care.
